Evidence based review of escitalopram in treating major depressive disorder in primary care
- 1 September 2004
- journal article
- research article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 19 (5) , 305-310
Abstract
The study aimed to summarize clinical data for escitalopram in the treatment of major depressive disorder in primary care. Medline, Embase and Cochrane databases were searched for randomized controlled trials of escitalopram (10–20 mg/day for 8 weeks) versus other antidepressants in therapeutic doses or placebo. Patients were required to have had moderate/severe depression, with Montgomery–Åsberg Depression Rating Scale (MADRS) scores recorded at baseline and 8 weeks. Outcomes examined were remission rates (MADRS≤12) and response rates (≥50% decrease from baseline in MADRS at week 8). Data were combined using a random effects meta-analytic model. Of the 15 studies identified, 11 were rejected (five not primary care, four duplicate reports, one lacked 8-week MADRS scores, one not depression) and four were accepted (n=1472 patients). The four studies had nine arms, four for escitalopram (n=654), two for citalopram (n=333), one for venlafaxine-XR (n=142) and two for placebo (n=343). Remission rates for escitalopram were superior to placebo (48.7% versus 37.6%, P=0.003) and citalopram (52.8% versus 43.5%, P=0.003) but similar to venlafaxine-XR (P=0.97). Response rates were superior to placebo (48.7% versus 43.1%, P0.05). Remission and response rates of escitalopram in primary care are clinically superior to placebo and citalopram, but similar to venlafaxine-XR. Further head-to-head trials are warranted to verify these findings. A pharmacoeconomic analysis is also required to determine whether these clinical advantages for the patients translate into economic advantages for the health care system.Keywords
This publication has 26 references indexed in Scilit:
- A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive DisorderNeuropsychobiology, 2004
- Escitalopram in the Treatment of Panic DisorderThe Journal of Clinical Psychiatry, 2003
- Depression in primary care patients: Improvement during long-term escitalopram treatmentEuropean Neuropsychopharmacology, 2002
- Escitalopram prevents relapse of depressive episodesEuropean Psychiatry, 2002
- Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat ModelBasic & Clinical Pharmacology & Toxicology, 2001
- The management of depression in primary health careCurrent Opinion in Psychiatry, 1999
- Depression in the communityInternational Clinical Psychopharmacology, 1997
- A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disordersClinical Therapeutics, 1995
- The costs of depressionInternational Clinical Psychopharmacology, 1993
- The Combination of Estimates from Different ExperimentsBiometrics, 1954